Phase II Clinical Trial of CD34+ Cell Therapy to Explore Endpoint Selection and Timing in Patients With Critical Limb Ischemia
Yasuyuki Fujita(Sapporo University), Atsuhiko Kawamoto(Northwestern University), Makoto Kinoshita(Nagoya University), Emiko Uno(Translational Research Informatics Center (Japan)), Douglas W. Losordo(MACOM (United States)), Hisako Hashimoto(Foundation for Biomedical Research and Innovation), Yasuo Kurimoto(Kobe City Medical Center General Hospital), Masanori Fukushima(Nagoya Institute of Technology), Yasuhiko Hirami(Foundation for Biomedical Research and Innovation), Yutaka Furukawa(Kobe City Medical Center General Hospital), Tohru Nagano(Kobe City Medical Center General Hospital), Kyosuke Arakawa(Okayama University), Takayuki Asahara(Shonan Kamakura General Hospital), Nobuyuki Katakami(Takarazuka City Hospital), Adel Nada(Baxter (United States)), Yoshihiro Matsubara(Translational Research Informatics Center (Japan)), Yukikatsu Okada, Kazuo Yamazaki(Institute for Biomedical Research and Innovation), Yutaka Okita(Takatsuki General Hospital)
Cited by 70
Related Papers
Gene Therapy for Myocardial Angiogenesis
|Circulation|1998|993
Angiogenesis and vasculogenesis as therapeutic strategies for postnatal neovascularization
|Journal of Clinical Investigation|1999|770
HMG-CoA reductase inhibitor mobilizes bone marrow–derived endothelial progenitor cells
|Journal of Clinical Investigation|2001|651
HMG-CoA reductase inhibitor mobilizes bone marrow–derived endothelial progenitor cells
|Journal of Clinical Investigation|2001|609